Persistence of Symptoms after Acute COVID-19 Infection- An Experience from a Tertiary Care Centre in South India

Areekal, Binu; Sukumaran, Sudhiraj Thiruthara; Andrews, Andrews Mekkattukunnel; Nanu, Sreejith Parayil; Madhavan, Indira; Veepanattu, Pranav; Parambath, idhin Raj; Solomon, Jobin Palluruthil

doi:10.7860/jcdr/2021/49600.14967

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 shows the details of the included studies with the study design, type of population, symptoms, duration, and the information provided. 13 – 62 Supplemental Table 2 shows the excluded studies with reasons of exclusion.…”

Section: Resultsmentioning

confidence: 99%

“…The frequency of loss of appetite as a part of long GI COVID was 0.09 (95% CI, 0.03–0.23, I 2 = 99%) in patients with COVID-19 infection while it was 0.20 (95% CI, 0.08–0.43, I 2 = 98%) in patients having long COVID. 15,16,22,29,33,36,37,39,40,54,57,61,62 The frequency of loss of taste as a part of long GI COVID was 0.10 (95% CI, 0.05–0.19, I 2 = 97%) in patients with COVID-19 infection while it was 0.17 (95% CI, 0.10–0.27, I 2 = 95%) in patients having long COVID 37–40,44,47,50,54,56,57,58,61 (Figure 3). The frequency of diarrhea as a part of long GI COVID was 0.05 (95% CI, 0.03–0.10, I 2 = 99%) in patients with COVID-19 infection while it was 0.10 (95% CI, 0.04–0.23, I 2 = 98%) in patients having long COVID 13–19,24,25,28,34,36–38,40,41,43,44,46,50,53,56,57,60,61,62 (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

“…15,16,22,29,33,36,37,39,40,54,57,61,62 The frequency of loss of taste as a part of long GI COVID was 0.10 (95% CI, 0.05–0.19, I 2 = 97%) in patients with COVID-19 infection while it was 0.17 (95% CI, 0.10–0.27, I 2 = 95%) in patients having long COVID 37–40,44,47,50,54,56,57,58,61 (Figure 3). The frequency of diarrhea as a part of long GI COVID was 0.05 (95% CI, 0.03–0.10, I 2 = 99%) in patients with COVID-19 infection while it was 0.10 (95% CI, 0.04–0.23, I 2 = 98%) in patients having long COVID 13–19,24,25,28,34,36–38,40,41,43,44,46,50,53,56,57,60,61,62 (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis

Choudhury

Tariq

Jena

et al. 2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Prolonged symptoms after COVID-19 are an important concern due to the large numbers affected by the pandemic. Objectives: To ascertain the frequency of gastrointestinal (GI) manifestations as part of long GI COVID. Design: A systematic review and meta-analysis of studies reporting GI manifestations in long COVID was performed. Data Sources and Methods: Electronic databases (Medline, Scopus, Embase, Cochrane Central Register of Controlled Trials, and Web of Science) were searched till 21 December 2021 to identify studies reporting frequency of GI symptoms in long COVID. We included studies reporting overall GI manifestations or individual GI symptoms as part of long COVID. We excluded pediatric studies and those not providing relevant information. We calculated the pooled frequency of various symptoms in all patients with COVID-19 and also in those with long COVID using the inverse variance approach. All analysis was done using R version 4.1.1 using packages ‘meta’ and ‘metafor’. Results: A total of 50 studies were included. The frequencies of GI symptoms were 0.12 [95% confidence interval (CI), 0.06–0.22, I2 = 99%] and 0.22 (95% CI, 0.10–0.41, I2 = 97%) in patients with COVID-19 and those with long COVID, respectively. The frequencies of abdominal pain, nausea/vomiting, loss of appetite, and loss of taste were 0.14 (95% CI, 0.04–0.38, I2 = 96%), 0.06 (95% CI, 0.03–0.11, I2 = 98%), 0.20 (95% CI, 0.08–0.43, I2 = 98%), and 0.17 (95% CI, 0.10–0.27, I2 = 95%), respectively, after COVID-19. The frequencies of diarrhea, dyspepsia, and irritable bowel syndrome were 0.10 (95% CI, 0.04–0.23, I2 = 98%), 0.20 (95% CI, 0.06–0.50, I2 = 97%), and 0.17 (95% CI, 0.06–0.37, I2 = 96%), respectively. Conclusion: GI symptoms in patients were seen in 12% after COVID-19 and 22% as part of long COVID. Loss of appetite, dyspepsia, irritable bowel syndrome, loss of taste, and abdominal pain were the five most common GI symptoms of long COVID. Significant heterogeneity and small number of studies for some of the analyses are limitations of the systematic review.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis

Choudhury

Tariq

Jena

et al. 2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…In the present study, majority of the patients i.e., 36% belong to 40-49 years age group and mean age was found to be 45 years, similar age group was considered in many studies. [8][9][10][11][12][13] In the present study, 72% of the patients were male and 28% were females. Male predominance was seen in different studies.…”

Section: Discussionmentioning

confidence: 81%

Clinical and radiological follow up of post-COVID patients in tertiary care centre

Penmetsa¹,

Yalamanchili²,

Yendapu³

et al. 2023

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: COVID-19 is potentially fatal infection caused by novel corona virus SARS COV2.SARS patients may present with a spectrum of symptoms and signs ranging from relatively asymptomatic to fulminant pneumonitis and death. Out of which, most frequent symptoms are cough, fever, myalgia, dyspnoea and altered smell/taste. The primary objective of the study is to describe the clinical evolution and symptoms persistence [at day 30 and day 60] during 2 months follow up in adults with COVID-19 and to follow up the changes in lung radiographic pictures within 2 months after discharge. Methods: This is an institutional based, prospective clinical observational study conducted in Asram medical college, Eluru from September 2021 to November 2021 on 25 COVID-19 Patients. Results: In our study two thirds of patients still reported symptoms at day 30 and half of the patients reported symptoms at day 60. Out of 50 patients, 38 (76%) patients had at least one symptom at day 30 and 25 (50%) patients had symptoms at day 60 and 9 (18%) patients had chest X-ray abnormalities during follow-up after 2 months. Conclusions: Follow up studies of COVID-19 will improve our understanding of natural history of COVID-19 sequelae and enable us to assess the efficacy of therapeutic interventions to mitigate the long-term consequences of COVID-19 It is necessary to follow up these recovered patients for detection and appropriate management towards their psychological, physical and social realm. It is highly important to provide counselling, moral support to restore to normalcy.

show abstract

“…Though it has emerged as a relevant PASC symptom, our study did not adequately capture symptoms of myalgia. Previous clinic-based studies conducted in India provided limited data as data collection was limited by clinic site, and sample sizes were <1500 25 – 27 . Therefore, the decentralized, remote recruitment and data collection methods utilized in Data4Life were fundamental to capturing a larger, more diverse representation of PASC in India.…”

Section: Methodsmentioning

confidence: 99%

Development of a decentralized cohort for studying post-acute sequelae of COVID-19 in India in the Data4life Study

Schilling,

Shokouhi,

Montgomery

et al. 2023

Commun Med

View full text Add to dashboard Cite

Background Decentralized, digital health studies can provide real-world evidence of the lasting effects of COVID-19 on physical, socioeconomic, psychological, and social determinant factors of health in India. Existing research cohorts, however, are small and were not designed for longitudinal collection of comprehensive data from India’s diverse population. Data4Life is a nationwide, digitally enabled, health research initiative to examine the post-acute sequelae of COVID-19 across individuals, communities, and regions. Data4Life seeks to build an ethnically and geographically diverse population of at least 100,000 participants in India. Methods Here we discuss the feasibility of developing a completely decentralized COVID-19 cohort in India through qualitative analysis of data collection procedures, participant characteristics, participant perspectives on recruitment and reported study motivation. Results As of June 13th, 2022, more than 6,000 participants from 17 Indian states completed baseline surveys. Friend and family referral were identified as the most common recruitment method (64.8%) across all demographic groups. Helping family and friends was the primary reason reported for joining the study (61.5%). Conclusions Preliminary findings support the use of digital technology for rapid enrollment and data collection to develop large health research cohorts in India. This demonstrates the potential for expansion of digitally enabled health research in India. These findings also outline the value of person-to-person recruitment strategies when conducting digital health research in modern-day India. Qualitative analysis reveals opportunities to increase diversity and retention in real time. It also informs strategies for improving participant experiences in the current Data4Life initiative and future studies.

show abstract

Persistence of Symptoms after Acute COVID-19 Infection- An Experience from a Tertiary Care Centre in South India

Cited by 4 publications

References 0 publications

Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis

Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis

Clinical and radiological follow up of post-COVID patients in tertiary care centre

Development of a decentralized cohort for studying post-acute sequelae of COVID-19 in India in the Data4life Study

Contact Info

Product

Resources

About